Pulmonary Fibrosis, Unspecified Clinical Trial
Official title:
Safety and Diagnostic Performance of 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-PRGD2 in lung injury (LI) and pulmonary fibrosis (PF) patients. A single dose of nearly 111 MBq 68Ga-NOTA-PRGD2 (≤ 40 µg NOTA-PRGD2) will be intravenously injected into patients with LI/PF. Visual and semiquantitative method will be used to assess the PET/CT images.
The αvβ3-integrin is a transmembrane heterodimeric receptor that mediates cell-cell and
cell-extracellular matrix adhesion. The αvβ3-integrin plays a pivotal role in promoting and
sustaining angiogenesis and fibrosis. Cyclic arginine-glycine-aspartic acid (RGD) peptide is
the key integrin recognition motif that can strongly bind to the αvβ3-integrin, which makes
the RGD-based peptides hold a promise for imaging and treatment of diseases characterised
with angiogenesis and fibrosis including LI and PF.
Animal study in bleomycin induced lung fibrosis showed good uptake ratio of 68Ga-NOTA-PRGD2
in lung vs background. For interests in clinical translation of 68Ga-NOTA-PRGD2, an
open-label dynamic whole-body PET/CT study was designed to investigate safety and diagnostic
performance of 68Ga-NOTA-PRGD2 in patients with LI or PF.
;